Loading...

Top
Help
×

By creating an account you can:

Logo TaxTMI
Call Us / Help / Feedback

Contact Us At :

E-mail: [email protected]

Call / WhatsApp at: +91 99117 96707

For more information, Check Contact Us

FAQs :

To know Frequently Asked Questions, Check FAQs

Most Asked Video Tutorials :

For more tutorials, Check Video Tutorials

Submit Feedback/Suggestion :

Email :
Please provide your email address so we can follow up on your feedback.
Category :
Description :
Min 15 characters 0/2000
Make Most of Text Search
  1. Checkout this video tutorial: How to search effectively on TaxTMI.
  2. Put words in double quotes for exact word search, eg: "income tax"
  3. Avoid noise words such as : 'and, of, the, a'
  4. Sort by Relevance to get the most relevant document.
  5. Press Enter to add multiple terms/multiple phrases, and then click on Search to Search.
  6. Text Search
  7. The system will try to fetch results that contains ALL your words.
  8. Once you add keywords, you'll see a new 'Search In' filter that makes your results even more precise.
  9. Text Search
Add to...
You have not created any category. Kindly create one to bookmark this item!
Create New Category
Hide
Title :
Description :
❮❮ Hide
Default View
Expand ❯❯
Close ✕
🔎 News - Adv. Search
TEXT SEARCH:

Press 'Enter' to add multiple search terms. Rules for Better Search

Search In:
Main Text + AI Text
  • Main Text
  • Main Text + AI Text
  • AI Text
Category: ?
Categorized by AI
---- All Categories ----
  • ---- All Categories ----
  • Income Tax
  • GST
  • Customs, DGFT & SEZ
  • FEMA & RBI
  • Corp. Laws, SEBI & IBC
  • PMLA, Black Money & ED
  • Budget
  • News and Press Release
  • PTI News
Month:
---- All Months ----
  • ---- All Months ----
  • January
  • February
  • March
  • April
  • May
  • June
  • July
  • August
  • September
  • October
  • November
  • December
Year:
---- All Years ----
  • ---- All Years ----
  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
Sort By: ?
In Sort By 'Default', exact matches for text search are shown at the top, followed by the remaining results in their regular order.
Relevance Default Date
❯❯
Maximize Maximize Maximize
0 / 200
Expand Note
Add to Folder

No Folders have been created

+

Are you sure you want to delete "My most important" ?

NOTE:

News
Showing Results for :
Reset Filters
Results Found:
Show All Summaries Hide All Summaries
March 25, 2026
Show AI Summary
Semiconductor wafer fabrication notification governs specified business status, mandatory filing, and tax benefits under the prescribed form.
Form 19 is the prescribed application for notification of a semiconductor wafer fabrication manufacturing unit as a specified business under section 46 of the Income-tax Act, 2025. It is required for assessee carrying on or proposing to carry on semiconductor wafer fabrication activity and is mandatory for claiming the associated tax benefits. The form seeks particulars of the assessee, the specified business, the proposed unit, commencement details, prescribed approvals, and confirmation that the unit is exclusively for semiconductor wafer fabrication, located in India, and operating under the required conditions.
March 25, 2026
Show AI Summary
Specified business notification for affordable housing projects requires electronic filing, supporting documents, and compliance verification.
Form 18 is the prescribed application for notification of an affordable housing project as a specified business under section 46. It is required to be furnished electronically by an assessee seeking such notification and captures particulars of the assessee, the specified business, the proposed project, and compliance with prescribed conditions. Supporting documents such as the development agreement, sanction letter, and layout approval are attached to assist verification. The application is examined for compliance before notification may be granted.
March 25, 2026
Show AI Summary
Affordable housing project notification through Form 18 is mandatory for claiming tax benefits under the specified business regime.
Form 18 is the prescribed application for notification of an affordable housing project as a specified business under section 46 of the Income-tax Act, 2025, and filing it is mandatory for availing the tax benefits available under that provision. The form requires the assessee to furnish particulars of the assessee, the specified business, the proposed project, compliance with prescribed conditions, and other project-related details, including project location, unit-wise area particulars, investment, title to land, development agreements, and a declaration certifying correctness of the information furnished.
March 25, 2026
Show AI Summary
Approval for research-linked income-tax benefits through Form No. 17 requires detailed filing, verification, and ongoing annual compliance.
Form No. 17 is the prescribed electronic application for an Indian company and for a research association, university, college or other institution seeking approval under the relevant income-tax framework. It requires verified filing within the prescribed time, detailed particulars of the applicant, research activities, income, expenditure, donations, and supporting documents. The prescribed authority may issue a deficiency notice, and after approval the entity must furnish annual research-related compliance details.
March 25, 2026
Show AI Summary
Form No. 17 approval applications require detailed disclosures, electronic filing, and ongoing compliance for research-related tax recognition.
Form No. 17 is the prescribed electronic application for approval under section 45(3)(b) for a company and section 45(4)(b) for a research association, university, college or other institution. The form requires disclosure of incorporation details, key persons, beneficial owners, registrations, research facilities, research projects, income and expenditure, together with prescribed enclosures and declarations. Approval remains subject to maintenance of books, audit and reporting obligations, compliance with conditions of approval, and the possibility of withdrawal if activities cease, become non-genuine, or are not carried out as required.
March 25, 2026
Show AI Summary
Scientific research donation certificates streamline deduction verification through annual donor-wise reporting, Form 16 linkage, and corrected issuance.
Form 16 serves as the annual donor-wise certificate for contributions made to prescribed institutions for scientific research and is used to support verification of deductions claimed under the Income-tax Act, 2025. The certificate records aggregate donations received during the tax year, is not a receipt for individual transactions, and operates separately from transaction-level acknowledgments issued by the institution. It is linked to Form 15, must be issued once in each tax year on or before 31 May, and may be corrected if errors are found.
March 25, 2026
Show AI Summary
Finance Bill 2026 advances budgetary approval as Lok Sabha passes the measure with government amendments.
Lok Sabha passed the Finance Bill 2026 with 32 government amendments, completing its role in the Budgetary approval process for 2026-27 and sending the Bill to the Rajya Sabha for further consideration. The Budget framework for 2026-27 provides for substantial expenditure and capital outlay, along with projected gross tax revenue, gross borrowing, and a lower fiscal deficit than the current fiscal year.
March 25, 2026
Show AI Summary
Annual donor certificate for scientific research requires electronic FORM 16, separate from receipts and subject to deduction conditions.
Prescribed undertakings or institutions covered by section 45(3) must issue FORM 16 as an annual certificate to donors for sums received for scientific research. The certificate is issued once for the relevant tax year, on or before 31 May immediately following that year, and records the aggregate donation, donor particulars, the institution's approval details, and the relevant clause of section 45(3). FORM 16 is distinct from FORM 15, may be corrected or revised, and does not by itself guarantee deduction to the donor.
March 25, 2026
Show AI Summary
Scientific research donation reporting under Form 15 requires annual filing, donor-wise particulars, and cross-verification of deductions.
Form 15 is a statutory annual information statement for prescribed undertakings or institutions receiving sums for scientific research, social science research or statistical research under the Income-tax Act, 2025. It must be furnished annually by the recipient institution and verified by the person authorised to verify its return of income, on or before 31st May following the relevant tax year. The form captures donor-wise and donation-wise particulars and serves as a primary data source for cross-verification of deductions claimed by donors, without itself conferring any deduction.
March 25, 2026
Show AI Summary
Scientific research donation reporting under FORM 15 requires annual electronic furnishing by the recipient institution.
FORM 15 is a prescribed annual statement to be furnished by a prescribed undertaking or institution in respect of sums received for scientific research during a tax year. It applies to eligible sums received for scientific, social science or statistical research, and not to charitable donations. The obligation lies with the recipient institution, the statement is to be furnished annually on or before 31st May, and it must include donor-wise particulars, approval details, and receipt information. Non-furnishing or incorrect furnishing may affect the donor's deduction and attract statutory consequences.
March 25, 2026
Show AI Summary
In-house R&D approval under Form 14 conditions tax deduction eligibility and links scientific recognition with compliance oversight.
Proposed Form 14 is the statutory approval order for an in-house research and development facility under section 45(2) of the Income-tax Act, 2025. Issued by the Department of Scientific and Industrial Research under Rule 29, it records the company's particulars, the facility details, DSIR recognition, and the grant of approval for the deduction framework. The approval is facility-specific, depends on continued DSIR recognition, and does not by itself establish deduction entitlement.
March 25, 2026
Show AI Summary
In-house research and development approval governs deduction claims subject to DSIR recognition and statutory compliance.
FORM 14 is the prescribed approval order issued by DSIR for a company's in-house research and development facility under section 45(2) read with Rule 29. It formally grants approval, records the scientific research to be undertaken, links the approval with DSIR recognition and the company's application, and supports a deduction claim subject to compliance with statutory conditions. The form is facility-specific, not a filing form, and may be withdrawn for non-compliance or withdrawal of DSIR recognition.
March 25, 2026
Show AI Summary
Scientific research and development audit reporting supports deduction claims through mandatory independent certification and account verification.
Proposed FORM 13 is the annual statutory audit report for an approved in-house scientific research and development facility under section 45(2) of the Income-tax Act, 2025. It is furnished by the company through an independent accountant and provides independent assurance on maintenance of separate accounts, correctness of capital and revenue expenditure, conformity with DSIR guidelines, and linkage with audited financial statements. FORM 13 is a mandatory supporting document for deduction claims and operates with FORM 11, FORM 14 and FORM 12 in the compliance framework.
March 25, 2026
Show AI Summary
In-house R&D audit report defines compliance for deduction claims through separate accounts and certified expenditure.
FORM 13 is the accountant's annual audit report for an approved in-house scientific research and development facility claimed under section 45(2). It certifies maintenance of separate accounts, correctness of expenditure, and conformity with DSIR guidelines, and must be attached with or furnished in support of the company's return of income. The form is a mandatory compliance requirement, but deduction remains subject to verification and assessment.
March 25, 2026
Show AI Summary
Research and development deduction reporting through Form 12 supports technical certification, expenditure verification, and compliance oversight.
Proposed Form 12 is the statutory reporting form through which the prescribed authority, acting under Rule 29, submits findings and certification regarding an approved in-house research and development facility to the jurisdictional Chief Commissioner of Income-tax. It operates within the compliance framework for deduction of expenditure on approved in-house R&D facilities under section 45(2) of the Income-tax Act, 2025 and records evaluation details, eligible expenditure and asset movements for verification of deduction claims.
March 25, 2026
Show AI Summary
Research and development deduction reporting through FORM 12 supports verification of eligible expenditure and compliance oversight.
FORM 12 is a statutory report furnished by the prescribed authority under section 45(2) read with Rule 29 for an approved in-house research and development facility. It is filed with the Chief Commissioner of Income-tax and records the facility's examination, recognition status, and eligible capital and revenue expenditure for verifying deduction claims. The form is not filed by the company and does not itself determine final allowability of deduction, which remains subject to departmental verification during processing or assessment.
March 25, 2026
Show AI Summary
In-house R&D facility approval framework under income tax law requires DSIR cooperation, audit compliance, and ongoing reporting.
FORM 11 sets out the statutory application and agreement framework for approval of in-house research and development facilities under section 45(2) of the Income-tax Act, 2025, read with Rule 29. It applies to eligible companies maintaining or proposing to maintain an in-house R&D facility and requires disclosure of company particulars, a DSIR agreement, and binding undertakings on audit, reporting, asset use, and compliance. Approval is facility-specific and remains subject to continued compliance, with DSIR serving as the prescribed authority for evaluation and oversight.
March 25, 2026
Show AI Summary
In-house research and development approval requires disclosure, audit, and ongoing compliance before deduction can be considered.
Form 11 is the prescribed application under Rule 29 for a company seeking to enter into an agreement with the Department of Scientific and Industrial Research for an in-house research and development facility under section 45(2). It requires disclosure of company particulars, R&D expenditure, facility details, research objectives, and undertakings on maintenance and audit of accounts. The form is generally a one-time approval application, but annual compliance continues through progress reports, audited accounts, and expenditure details. Approval does not itself secure deduction, which depends on statutory conditions, the agreement, and verification.
March 25, 2026
Show AI Summary
Statutory reporting for approved scientific research programmes under FORM 10 strengthens tax oversight and compliance monitoring.
Proposed FORM 10 is the statutory reporting form furnished by the prescribed authority to the Income-tax Department for approved scientific research programmes under section 45(3)(c) of the Income-tax Act, 2025. It functions as the oversight stage after FORM 7 and FORM 8, linking approvals with departmental monitoring of payments, utilisation and deduction claims. The form is furnished electronically to the jurisdictional Chief Commissioner within the prescribed time and records the essential particulars of the approved programme, while not conferring any entitlement on the sponsor or replacing the approval order.
March 25, 2026
Show AI Summary
Scientific research programme approval reporting under tax law supports compliance monitoring, deduction verification, and administrative recordkeeping.
FORM 10 is a statutory report furnished by the prescribed authority in relation to a scientific research programme approved under section 45(3)(c) read with Rule 30. It is a post-approval monitoring instrument, furnished to the Chief Commissioner of Income-tax having jurisdiction over the sponsor within the prescribed time. The form records approval details, programme particulars, conditions of approval, and supports administrative monitoring, compliance verification, and cross-checking of deduction claims. It does not alter or substitute the approval granted under FORM 8.

News

Back

All News

Showing Results for :
Reset Filters
No Records Found

News

Back

All News

Showing Results for : Reset Filters

Axis Max Life Reports 20% YoY Growth in Individual Adjusted First Year Premium in 9M FY'26; VNB Increases by 30% YoY

February 17, 2026

Contents
Summary
Note

Note

-

Bookmark

Print

Print

Noida, Uttar Pradesh, India (NewsVoir) 9-Months Financial Year 2026 (“9M FY’26”) Highlights: • Max Financial Services Limited reports 18% growth in consolidated revenue excluding investment income • Axis Max Life continues outperforming private industry; Private market share increases by 53 bps to 9.8% • Individual Adjusted First Year Premium at ₹6,396 crores, grew 20% YoY • Gross Written Premium: ₹25,195 crores, up 18% Year-on-Year (YoY) • Measure of profitability – Value of New Business (VNB) at ₹1,633 crores with a YoY growth of 30% • New business margin improved to 23.6%; Total APE growth of 21% achieved • Embedded Value at ₹28,110 crores, grew 16% with an Operating RoEV of 16.9% • Individual New Business Sum Assured grew by 41% • Assets Under Management (AUM) at ₹1.93 lakh crores, up by 12% YoY Max Financial Services Limited has recorded consolidated revenue excluding investment income at ₹24,625 crores, growing 18% year-on-year in 9M FY’26. The consolidated revenue including investment income stands at ₹36,891 crores and consolidated Profit after Tax (PAT) at ₹137 crores in 9M FY’26. Continuing to outpace the private life insurance industry in 9M FY’26, Axis Max Life Insurance Limited, formerly known as Max Life Insurance Company Limited (“Axis Max Life” / “Company”), has reported new business growth (Individual Adjusted First Year Premium) of 20% in 9M FY’26, reaching ₹6,396 crores. This has resulted in a private market share gain of 53 basis points (bps) to 9.8%. As one of the fastest growing life insurers, Axis Max Life has delivered a 21% YoY Annualized Premium Equivalent (APE) growth in the first nine months of the fiscal. This strong performance was driven by secular growth in its proprietary channels and the scaling up of new partnerships established over the past few years. In the fiscal, Axis Max Life has secured 51 new business partnerships including 24 Group and 27 Retail partnerships. Further, in 9M FY’26, Axis Max Life’s individual renewal premium grew by 17% to ₹15,551 crores, taking the Gross Written Premium to ₹25,195 crores, an 18% YoY increase. Additionally, the Company has reported New Business Margins of 23.6% in 9M FY’26 up from 21.9% during the same period last year. The Value of New Business, a measure of profitability, experienced a YoY growth of 30%, aided by improvements in product mix. Axis Max Life led the industry in Retail protection sales and has maintained leadership in the online market, in both protection and savings categories. Sumit Madan, Managing Director and Chief Executive Officer, Axis Max Life, said, "Axis Max Life’s 9M FY’26 performance reflects the strength of a well-defined strategy executed with discipline and consistency. We delivered sustained double-digit growth outpacing the private life insurance industry, emerging as the fastest-growing player among the top ten insurers and achieving the highest market share gains in the sector. This growth is driven by the strength of our Individual Adjusted First Year Premium and Value of New Business, supported by broad-based expansion across proprietary channels. Our Agency vertical remains the industry’s fastest-growing, with continued momentum across our strategic partnership businesses. As we scale, our commitment to delivering value to investors and customers remains steadfast. We are sharpening our competitive edge by focusing on elevating the customer experience through continuous digital innovation. This remains the primary engine driving our long-term growth and market leadership.” Key Financial Summary of Axis Max Life: ₹ Crores 9M FY’26 9M FY’25 YoY Financial performance Summary Individual Adjusted FYP 6,396 5,352 20% Total APE 6,908 5,731 21% Renewal Premium 15,551 13,269 17% Gross Written Premium 25,195 21,360 18% Number of Policies (000's) 638 540 18% Individual New business Sum Assured 3,67,679 2,59,925 41% Assets Under Management 1,92,688 1,71,705 12% Embedded Value 28,110 24,129 16% RoEV 16.9% 17.3% -40 bps New Business Margins 23.6% 21.9% 175 bps Value of new business 1,633 1,255 30% Solvency 201% 196% 500 bps About Max Financial Services Limited (https://maxfinancialservices.com) Max Financial Services Limited (MFSL) is part of India’s leading business conglomerate - the Max Group. Focused on Life Insurance, MFSL owns and actively manages an ~81% majority stake in Axis Max Life. MFSL is listed on the NSE and BSE. Besides a ~1.25% holding by Analjit Singh and sponsor family, some of the other group shareholders include MSI, Capital Group, Vanguard, Polar, Pictet, Jupiter, Blackrock, Kuwait Investment Authority, Abu Dhabi Investment Authority, Franklin Templeton, Pioneer, JP Morgan, Norges Bank, Principal Funds, BNP Paribas, Canada Pension Fund, MIT, Asset Management Companies - HDFC, Nippon, ICICI Prudential, DSP, SBI, Kotak, Aditya Birla Sun Life, Mirae, UTI, Canara Robeco, Invesco, HSBC, Whiteoak, Edelweiss, TATA, Bandhan, Abakkus and PGIM, and Private Life Insurance Companies – HDFC, SBI, TATA AIA, Kotak, ICICI Pru, Bajaj Allianz, Canara HSBC and Aditya Birla Sun Life. Company Information Number - L24223PB1988PLC008031 About Axis Max Life Insurance Limited (https://www.axismaxlife.com) Axis Max Life Insurance Limited, formerly known as Max Life Insurance Company Ltd., is a Joint Venture between Max Financial Services Limited (“MFSL”) and Axis Bank Limited. Axis Max Life offers comprehensive protection and long-term savings life insurance solutions through its multi-channel distribution, including agency and third-party distribution partners. It has built its operations over two decades through a need-based sales process, a customer-centric approach to engagement and service delivery and trained human capital. As per annual audited financials for FY2024-25, Axis Max Life has achieved a gross written premium of INR 33,223 Cr. IRDAI Registration. No – 104 Company Information Number - U74899PB2000PLC045626 Disclaimer This document has been prepared by Max Financial Services Limited (the “Company”) solely for the announcement of the Company’s financial results. This document contains certain forward-looking statements relating to the Company that are based on the beliefs of the Company’s management as well as assumptions made by and information currently available to the Company’s management. These forward-looking statements are, by their nature, subject to significant risks and uncertainties. When used in this document, the words “anticipate”, “believe”, “could”, “estimate”, “expect”, “going forward”, “intend”, “may”, “ought” and similar expressions, as they relate to the Company or the Company’s management, are intended to identify forward-looking statements. These forward-looking statements reflect the Company’s views as of the date of the Presentation with respect to future events and are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. Actual results and events may differ materially from information contained in the forward-looking statements. The Company assumes no obligation to update or otherwise revise these forward-looking statements for new information, events or circumstances that occur subsequent to the date of the Presentation. No representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. The information and opinions contained herein are subject to change without notice. None of Company or any of its directors, officers, employees, agents or advisers, or any of their respective affiliates, advisers or representatives, undertake to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise and none of them shall have any liability (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. This document does not constitute or form part of, and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company or any of its subsidiaries or affiliates in any jurisdiction or an inducement to enter into investment activity. No part of this document, nor the fact of its distribution, shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. The information herein is given to you solely for your own use and information, and no part of this document may be copied or reproduced, or redistributed or passed on, directly or indirectly, to any other person in any manner or published, in whole or in part, for any purpose. Axis Max Life Insurance Limited (formerly known as Max Life Insurance Company Limited) is a Joint Venture between Max Financial Services Limited ("MFSL") and Axis Bank Limited. Corporate Office: 11th Floor, DLF Square Building, Jacaranda Marg, DLF City Phase II, Gurugram (Haryana) - 122 002. For more details on risk factors, Terms and Conditions please read the prospectus carefully before concluding a sale. You may be entitled to certain applicable tax benefits on your premiums and policy benefits. Please note all the tax benefits are subject to tax laws prevailing at the time of payment of premium or receipt of benefits by you. Tax benefits are subject to changes in tax laws. You can call us on our Customer Helpline No. 1860 120 5577. Website: https://www.axismaxlife.com IRDAI Registration. No – 104 CIN number (U74899PB2000PLC045626) (Disclaimer: The above press release comes to you under an arrangement with Newsvoir and PTI takes no editorial responsibility for the same.). PTI

Topics

Acts Income Tax